DMV Region Emerges as Powerhouse for Biopharma Innovation
The DMV (District of Columbia, Maryland, and Virginia) region has established itself as a thriving hub for biopharmaceutical innovation, particularly in emerging clinical trial operations. At the heart of this ecosystem lies a remarkable concentration of clinical-stage biopharma companies, with Zymewire's recent analysis identifying 335 such organizations operating in the area.
This density of clinical development activity is no coincidence. The region benefits from a unique confluence of factors: proximity to the FDA, a rich talent pool from prestigious research institutions including Johns Hopkins and the University of Maryland, and a robust healthcare infrastructure featuring world-class medical centers.
The growing significance of the DMV's clinical trial landscape has attracted attention from pharmaceutical industry leaders, with AstraZeneca, GSK, and Johnson & Johnson having located sites in the region.
Taking place in May 2025, The PBC Group's launch of COG DMV, will provide the region's Biopharma with a dedicated conference focused on clinical trial operations. Set to take place in Bethesda, Maryland, this event underscores the region's emergence as a focal point for clinical research innovation and operational excellence.
The conference aims to facilitate knowledge sharing and collaboration among the area's diverse stakeholders, from emerging biotechs to established pharmaceutical companies. By bringing together the DMV's clinical operations community, COG DMV represents a significant step toward strengthening the region's position as a leading destination for clinical trial execution and innovation.
Get Involved
When: 13th & 14th May, 2025Â
How to get involved:
Event Homepage: www.thepbcgroup.com/cog-dmv
Present on the Program – Chloe Adams (cda@thepbcgroup.com)
Sponsorship & Exhibiting – Alexander O'Leary (aol@thepbcgroup.com)
Register to Attend - www.thepbcgroup.com/registration-page
Comments